Simcere Pharmaceutical Group Limited (HKG:2096)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
13.00
+0.66 (5.35%)
Jul 28, 2025, 4:09 PM HKT
5.35%
Market Cap32.17B
Revenue (ttm)7.06B
Net Income (ttm)780.21M
Shares Out2.47B
EPS (ttm)0.31
PE Ratio42.12
Forward PE25.69
Dividend0.18 (1.42%)
Ex-Dividend DateJun 18, 2025
Volume18,138,000
Average Volume21,199,344
Open12.34
Previous Close12.34
Day's Range12.34 - 13.00
52-Week Range5.08 - 13.36
Beta0.55
RSI68.39
Earnings DateAug 21, 2025

About HKG:2096

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENW... [Read more]

Sector Healthcare
Founded 1995
Employees 6,584
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2096
Full Company Profile

Financial Performance

In 2024, HKG:2096's revenue was 6.64 billion, an increase of 0.41% compared to the previous year's 6.61 billion. Earnings were 733.17 million, an increase of 2.57%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.